Unlock insights for autoimmune therapiesWith easily accessible blood samples
Deep immune profiling paired with a robust analysis platform can unlock actionable insights for therapy development. This data is now measurable in peripheral blood through the TokuProfile.
Understanding how a therapy works at a cellular level can improve trial design and accelerate candidates to approval.
Immune monitoring has emerged as an essential tool for the development of autoimmune therapies.
Mass cytometry reveals systemic and local immune signatures that distinguish inflammatory bowel diseases
Candidate Markers for Stratification and Classification in Rheumatoid Arthritis
Cytometry by time of flight identifies distinct signatures in patients with systemic sclerosis, systemic lupus erythematosus and Sjögrens syndrome
Accelerate the Pipeline
- Discovery Mechanism of action
Mechanism of resistance
- Phase I/II ID response characteristics
Novel pathway identification
- Phase III Likelihood for Response
Likelihood for Adverse Events
Novel Pathway Identification – Cancer Example
A TokuProfile™ Can Reveal Unique Insights
The assumption is that CD8 T-cells need to be targeted directly. However, this leads to therapy failure.
Profiling reveals that even though CD8 T-cells appear suppressed, the actual issue is with the Dendritic Cells not being active.
Anti CD40 Therapy Activates Dendritic Cells to create therapy success.